Myriad Genetics Announces Third Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

Core Insights - Myriad Genetics has received a third patent for its tumor-informed, high-definition molecular residual disease (MRD) assay, enhancing its market capabilities [1][2] - The new patent, U.S. patent no. 12,104,212, focuses on personalized methods for detecting circulating tumor DNA (ctDNA), showcasing Myriad's commitment to advancing its MRD strategy [1][2] - The Precise MRD assay is designed to track thousands of tumor-specific variants, allowing for lower-level ctDNA detection compared to existing market products [2] Company Developments - Myriad Genetics is leveraging its existing technology, including the FDA-approved MyChoice® CDx and FirstGeneTM platforms, to develop the Precise MRD assay [2] - The company is conducting high-impact studies for the Precise MRD assay and transitioning to a new laboratory facility in Salt Lake City [2] - Collaborations for MRD studies include partnerships with Memorial Sloan Kettering, The University of Texas MD Anderson Cancer Center, and the National Cancer Center Hospital East in Japan [2][3] Industry Context - The MRD market is characterized as emerging and under-penetrated, presenting significant opportunities for Myriad to advance oncology care [2] - Myriad Genetics aims to commercialize the Precise MRD assay profitably, addressing the needs of cancer patients and biopharma companies [2]